Lanean...
Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study
Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by autonomic failure and parkinsonism/ataxia; no treatment exists to slow disease progression. A number of factors have prevented or compromised trials targeting disease modification. A major hurdle has been uncertaint...
Gorde:
| Argitaratua izan da: | Clin Auton Res |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4763681/ https://ncbi.nlm.nih.gov/pubmed/25763826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10286-015-0281-2 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|